MONTREAL —Tirzepatide (Mounjaro, Eli Lilly), the dual gastric inhibitory polypeptide–glucagon-like peptide 1 (GIP–GLP-1) receptor agonist that has shown significant benefits in diabetes and obesity, may also...
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030...